Mads Tang-Christensen

Mads Tang-Christensen has a long work experience, beginning in 1999 as a Post Doc and Post Dotoral Fellow at University of Copenhagen, and a Læge at ccbr. In 2002 they became a Manager Pharmacology and Director Contract Research and External Affairs at Rheoscience. In 2008 they were appointed CEO at gubra. From 2010 to 2022, they worked at Novo Nordisk, in various roles, including Scientific Vice President, Corporate Vice President; Therapeutic Area Head Global Obesity and Liver Disease Research, Corporate Vice President Therapeutic Area Head Obesity, Vice President Obesity and Liver Disease Novo Nordisk, Scientific Vice President Obesity; chairman of Obesity Focus Group, Vice President Incretin and Obesity Research, Vice President Diabetes and Obesity Biology, and Vice President Diabetes Biology. In 2022, they were appointed EIR at BiOrigin, Advisor and Chief Scientist at Antag Therapeutics, Owner/CEO at MTC Holding Aps, and Adjunct Professor at Monash University. Mads is also Chief Development Officer (CDO) at Embark Biotech.

Mads Tang-Christensen received their MD and PhD in integrative neuroendocrinology from Københavns Universitet - University of Copenhagen between 1996 and 1999. Prior to this, they attended Odsherreds Gymnasium from 1982 to 1985.